奥德赛制药

最新新闻

• 评级变动
  TD Cowen Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)
  TipRanks · 2026/8/6
• 评级变动
  Wedbush Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Metagenomi, Inc. (MGX) and Autolus Therapeutics (AUTL)
  TipRanks · 2026/8/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)
  TipRanks · 2026/6/18
• H.C. Wainwright Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• H.C. Wainwright Initiates Odyssey Therapeutics(ODTX.US) With Buy Rating, Announces Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Oppenheimer Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  A Quick Look at Today's Ratings for Odyssey Therapeutics(ODTX.US), With a Forecast Between $16.96 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• H.C. Wainwright Keeps Their Buy Rating on Odyssey Therapeutics, Inc. (ODTX)
  TipRanks · 2026/9/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。